Sensus Healthcare (SRTS) AI Stock Analysis

• Market Cap: $63.24M
• Dividend Yield: N/A
• Average Volume (3M): 113.02K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.93
• Revenue Growth: -13.79%
• EPS Growth: -132.21%
• Country: US
• Employees: 54
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.19
• Shares Outstanding: 16,425,035
• 10 Day Avg. Volume: 122,241
• 30 Day Avg. Volume: 113,021
• PEG Ratio: 0.04
• Price to Book (P/B): 1.35
• Price to Sales (P/S): 2.36
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.65
• Enterprise Value/Revenue: 1.50
• Enterprise Value/Gross Profit: 3.48
• Enterprise Value/Ebitda: -6.16
• 1Y Price Target: $6.00
• Price Target Upside: 70.45% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): -0.06
• Revenue Forecast (FY): $32.17M

• Rating: 65 Neutral
• Price Target: $5.00 ▲(42.05% Upside)
• Action: Reiterated Date: 12/09/25
• Date: Action: Reiterated 12/09/25

Sensus Healthcare's overall score reflects strong financial performance and strategic corporate developments, tempered by challenges in cash flow management and valuation concerns. Technical indicators suggest caution, while the earnings call presents a mixed outlook with both positive and negative elements.

Positive Factors

New CPT Codes

The introduction of new CPT codes significantly increases reimbursement rates, enhancing the attractiveness of SRT systems and potentially driving higher sales and market penetration.

International Expansion

Efforts to expand internationally, especially in large markets like China, position Sensus Healthcare for long-term growth and diversification of revenue streams.

Leadership Appointment

The appointment of Sardano to oversee global sales and strategy is likely to strengthen commercial execution and capitalize on recent reimbursement milestones.

Negative Factors

Revenue Decline

A decline in revenue suggests challenges in maintaining sales momentum, which could impact future growth and profitability if not addressed.

Increased Operating Expenses

Rising operating expenses, driven by higher IT and R&D costs, may pressure margins and require careful management to sustain profitability.

Negative Cash Flow

Persistent negative cash flow indicates ongoing challenges in cash generation, which could limit the company's ability to invest in growth initiatives.

Sensus Healthcare Business Overview & Revenue Model

Company Description

Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a SRT-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and in-office laser rental services. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.

How the Company Makes Money

Sensus Healthcare generates revenue through the sale of its medical devices and systems, specifically the Sensus system, which is used for non-invasive skin cancer treatment. The company's revenue model is primarily based on direct sales to healthcare providers, including hospitals, outpatient surgical centers, and dermatology practices. In addition to device sales, Sensus Healthcare also earns revenue through recurring sales of consumables and accessories that accompany its treatment systems. Strategic partnerships with healthcare institutions and distributors enhance the company's reach and facilitate market penetration, while ongoing research and development efforts aim to expand its product offerings and improve existing technologies, contributing to future growth and revenue streams.

Sensus Healthcare Financial Statement Overview

Summary

Sensus Healthcare shows strong revenue and profit growth, with a robust balance sheet characterized by low leverage and high equity. However, cash flow remains a challenge due to negative free cash flow, indicating a need for improved cash management.

Income Statement

Sensus Healthcare showed remarkable revenue growth of 71.3% from the previous year. The gross profit margin improved significantly to 58.4%, reflecting increased operational efficiency. Net profit margin also improved substantially to 15.9%, indicating enhanced profitability. However, the EBIT margin of 19.3% and EBITDA margin of 19.3% suggest room for improvement in controlling operating expenses.

Balance Sheet

The company maintains a strong equity position with an equity ratio of 89.8%, demonstrating financial stability. The debt-to-equity ratio is low at 0.01, indicating minimal leverage and reduced financial risk. Return on equity improved significantly to 11.9%, showcasing effective utilization of shareholder funds. Overall, the balance sheet reflects solid financial health.

Cash Flow

Sensus Healthcare's free cash flow improved but remains negative, indicating potential challenges in cash management. The operating cash flow to net income ratio is negative, suggesting a need to enhance cash generation from operations. Despite these challenges, the free cash flow deficit has narrowed, showing some progress towards achieving positive cash flows.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	27.48M	41.81M	24.41M	44.53M	27.04M
Gross Profit	11.87M	24.43M	14.06M	29.63M	16.99M
EBITDA	-9.92M	8.52M	79.00K	15.34M	4.73M
Net Income	-7.72M	6.65M	485.00K	24.24M	4.12M
Balance Sheet
Total Assets	53.04M	62.16M	53.71M	56.73M	32.24M
Cash, Cash Equivalents and Short-Term Investments	22.08M	22.06M	23.15M	25.52M	14.52M
Total Debt	680.00K	602.00K	783.00K	1.02M	225.00K
Total Liabilities	4.94M	6.34M	4.87M	8.67M	6.22M
Stockholders Equity	48.10M	55.83M	48.84M	48.07M	26.02M
Cash Flow
Free Cash Flow	0.00	-1.11M	-2.37M	-1.57M	-414.00K
Operating Cash Flow	0.00	-831.00K	-2.15M	-1.41M	-286.00K
Investing Cash Flow	0.00	-276.00K	-187.00K	14.84M	129.00K
Financing Cash Flow	0.00	15.00K	-40.00K	-2.43M	-231.00K

Sensus Healthcare Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.52
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SRTS, the sentiment is Negative. The current price of 3.52 is below the 20-day moving average (MA) of 4.70, below the 50-day MA of 4.44, and below the 200-day MA of 4.15, indicating a bearish trend. The MACD of -0.19 indicates Positive momentum. The RSI at 34.40 is Neutral, neither overbought nor oversold. The STOCH value of 22.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SRTS.

Sensus Healthcare Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SRTS	65 Neutral	$63.24M	-8.27	-14.85%	―	-13.79%	-132.21%
HYPR	59 Neutral	$110.77M	-2.21	-94.03%	―	-20.10%	7.87%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NSPR	47 Neutral	$73.30M	-2.07	-87.61%	―	14.04%	-0.65%
RBOT	45 Neutral	$13.52M	-0.20	-148.93%	―	―	15.03%
ICCM	45 Neutral	$39.86M	-2.27	-157.91%	―	-18.96%	8.98%
CTSO	44 Neutral	$40.73M	-3.41	-96.15%	―	-8.97%	47.29%

Sensus Healthcare Corporate Events

Sensus Healthcare Appoints Eric Sachetta as Director

On November 10, 2025, Sensus Healthcare appointed Eric Sachetta as a Class II director, filling the vacancy left by the late William McCall. Mr. Sachetta, a seasoned financial executive and Chief Wealth Services Officer at Sachetta, LLC, brings a wealth of experience in organizational growth and financial planning. His appointment is expected to enhance Sensus Healthcare’s strategic growth and operational excellence, aligning with the company’s mission to expand its SRT technology and global vision. The announcement was made public on November 12, 2025.

The most recent analyst rating on (SRTS) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Sensus Healthcare stock, see the SRTS Stock Forecast page.